

# **Vaccine Protection Against the SARS-CoV-2 Omicron Variant in Macaques**

**Dan H. Barouch, M.D., Ph.D.**

**Director, Center for Virology and Vaccine Research**

**Beth Israel Deaconess Medical Center**

**William Bosworth Castle Professor of Medicine**

**Harvard Medical School**

**Ragon Institute of MGH, MIT, and Harvard**


**WHO Global Consultation, Geneva, Switzerland**

**February 14, 2022**


# **Vaccine Protection Against SARS-CoV-2 Omicron in Macaques**

- **Goal: To evaluate the protective efficacy and immune correlates of mRNA and adenovirus vaccines against Omicron**
- **30 cynomolgus macaques (N=6/group)**
  - **BNTx3: BNT162b2 (week 0, 3, 14)**
  - **BNTx2/Ad26: BNT162b2 (weeks 0, 3), Ad26.COVS.S (week 14)**
  - **Ad26/BNT: Ad26.COVS.S (week 0), BNT162b2 (week 14)**
  - **Ad26x2: Ad26.COVS.S (week 0, 14)**
  - **Sham: Sham (weeks 0, 3, 14)**
- **High-dose  $10^6$  PFU SARS-CoV-2 Omicron challenge at week 19 by the IN+IT routes (challenge stock provided by Mehul Suthar, Emory)**



# Study Outline





# Pseudovirus NAb Responses




# CD8+ T Cell Responses





# CD4+ T Cell Responses



# Viral Loads (sgRNA) in BAL




# Peak and Day 4 Viral Loads (sgRNA) in BAL









# Viral Loads (sgRNA) in Nasal Swabs




# Peak and Day 4 Viral Loads (sgRNA) in Nasal Swabs




## Day 2 Infectious Virus Titers (TCID50)







# Immunologic Profile of Vaccine Failures







# Immunologic Profile of Vaccine Failures Suggests Role of Antibodies and CD8 T Cells in Protection



# Antibody Correlates of Protection



# T Cell Correlates of Protection



# **Vaccine Protection Against SARS-CoV-2 Omicron in Macaques**

- **Rapid virologic control in vaccinated macaques in lower respiratory tract following SARS-CoV-2 Omicron challenge**
- **Significant virologic control by heterologous vaccine regimens (BNT/Ad26, Ad26/BNT) in upper respiratory tract**
- **BNT162b2 induced higher antibody responses; Ad26.COV2.S induced higher CD8 T cell responses**
- **Both antibody and CD8 T cell responses correlated with virologic control; virologic failure in upper respiratory tract associated with moderate NAb titers and low CD8 T cell responses**



# Acknowledgements

## CVVR, Beth Israel Deaconess

Abishek Chandrashekar

Jingyou Yu

Katherine McMahan

Catherine Jacob-Dolan

Jinyan Liu

Xuan He

David Hope

Tochi Anioke

Julia Barrett

Benjamin Chung

Nicole P. Hachmann

Michelle Lifton

Jessica Miller

Olivia Powers

Michaela Sciacca

Daniel Sellers

Mazuba Siamatu

Nehalee Surve

Haley VanWyk

Huahua Wan

Cindy Wu

## Bioqual

Laurent Pessaint

Daniel Valentin

Alex Van Ry

Jeanne Muench

Mona Boursiquot

Anthony Cook

Jason Velasco

Elyse Teow

Mark G. Lewis

Hanne Andersen

## Washington University

Adrianus C.M. Boon

## Emory University

Mehul S. Suthar

## Tufts University

Neharika Jain

Amanda J. Martinot

## Funding

NIAID

NCI

MassCPR

Ragon Institute